(19)
(11) EP 3 981 402 A8

(12) CORRECTED EUROPEAN PATENT APPLICATION
published in accordance with Art. 153(4) EPC

(15) Correction information:
Corrected version no 1 (W1 A1)

(48) Corrigendum issued on:
08.06.2022 Bulletin 2022/23

(43) Date of publication:
13.04.2022 Bulletin 2022/15

(21) Application number: 21745202.8

(22) Date of filing: 01.06.2021
(51) International Patent Classification (IPC): 
A61K 31/454(2006.01)
A61K 9/00(2006.01)
 A61K 31/444(2006.01)
A61P 31/10(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 31/454; A61K 31/444; A61P 31/10; A61K 9/00
(86) International application number:
PCT/KR2021/006785
(87) International publication number:
WO 2022/035031 (17.02.2022 Gazette 2022/07)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 14.08.2020 KR 20200102603
09.02.2021 WO PCT/KR2021/001702

(71) Applicant: BL&H Co., Ltd.
Seoul 08594 (KR)

(72) Inventor:
  • Chang, Byeung Mo
    Seoul 04202 (KR)

(74) Representative: Office Freylinger 
P.O. Box 48
8001 Strassen
8001 Strassen (LU)

   


(54) PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF TINEA


(57) The composition of the present invention has a wide range of antimicrobial effects including antifungal against Trichophyton rubrum, Trichophyton mentagrophytes, Aspergillus niger, Candida albicans, Epidermophyton floccosum and Microsporum canis, which cause Tinea, and antibacterial effects against Pseudomonas aeruginosa, causative bacteria of green nail syndrome, and has excellent drug permeability to the skin and nail, so it can be used as a therapeutic agent for Tinea unguium, Tinea corporis and green nail syndrome.
In addition, since the pharmaceutical composition of the present invention does not undergo changes in physical properties even when stored at 65°C for 5 weeks or more, the stability of the composition can be ensured.